← Leaderboards
Lutz Tautz
Sanford Burnham Prebys Medical Discovery Institute
$6,319,255
Attributed
$7,792,934
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,792,934 · 8
By mechanism
RF1$2,947,358 · 1
R01$2,712,313 · 1
R21$2,011,763 · 4
R03$121,500 · 2
Top collaborators
- Nicholas David Cosford2 shared
Most similar at Sanford Burnham Prebys Medical Discovery Institute
Same institution · by research overlap
- Nicholas David Cosford$46,036,569
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposProtein Tyrosine PhosphatasePhosphoric Monoester HydrolasesBaseCellsMouse ModelIn VivoEnzymesPharmaceutical PreparationsSmall MoleculePhosphatase InhibitorToxic EffectStructureDrug DiscoveryTargeted TreatmentReportingInhibitor/AntagonistGeneticPropertyKnockout MiceAllosteric SiteLeadNeurodegenerative DisordersFunctional Disorder
Grant awards (15)
Fragment-Based Discovery of STEP Modulators in Alzheimer's Disease Administrative Supplement$111,976
RF1 · FY2025 · AG · contact PI
Fragment-based discovery of STEP modulators in Alzheimer's disease$2,835,382
RF1 · FY2024 · AG · contact PI
Development of STEP Allosteric Inhibitors as Novel Therapeutics for Alzheimer's Disease$851,505
R01 · FY2022 · AG · contact PI
Targeting the VHR phosphatase for the treatment of sepsis in COVID-19 patients$243,750
R21 · FY2022 · AI · contact PI
Development of STEP Allosteric Inhibitors as Novel Therapeutics for Alzheimer's Disease$902,529
R01 · FY2021 · AG · contact PI
Targeting the VHR phosphatase for the treatment of sepsis in COVID-19 patients$292,500
R21 · FY2021 · AI · contact PI
Development of STEP Allosteric Inhibitors as Novel Therapeutics for Alzheimer's Disease$958,279
R01 · FY2020 · AG · contact PI
Development of STEP substrates and probes as novel tools and therapeutics for Alzheimer's disease$536,250
R21 · FY2020 · AG · contact PI
Allosteric inhibition of the SHP2 oncoprotein in breast cancer$212,063
R21 · FY2017 · CA · contact PI
Allosteric inhibition of the SHP2 oncoprotein in breast cancer$254,475
R21 · FY2016 · CA · contact PI
STEP inhibitors for intervention in Alzheimer's Disease$48,750
R03 · FY2012 · MH · contact PI
STEP inhibitors for intervention in Alzheimer's Disease$47,750
R03 · FY2011 · MH · contact PI
Novel Delivery Technology for Potential Drugs for Cervical Cancer$214,875
R21 · FY2009 · CA · contact PI
Novel Delivery Technology for Potential Drugs for Cervical Cancer$257,850
R21 · FY2008 · CA · contact PI
Small-Molecule Inhibitors of Vaccinia-H1-Related Phosphatase VHR$25,000
R03 · FY2008 · MH · contact PI